FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)

View source ↗

Summary

The FDA approved a supplemental application for NEURACEQ (florbetaben F-18), expanding labeling to support its use as a PET imaging agent to visualize beta-amyl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• NEURACEQ (Florbetaben F 18)

Snippet

SUPPL AP for NEURACEQ (FLORBETABEN F 18)